MG Flashcards
(72 cards)
1
Q
danger zone ?
A
med/inf FG tx. where ca hide
2
Q
where does most BCA start
A
TDLU
3
Q
MCL of ectopic Br tx
A
axilla
2nd: infamammary fold
4
Q
modality of choice in pregnant or lactating lady ?
A
US
dense Br»_space; low MG Sn
5
Q
MCL of galactocele?
A
subareoloar
6
Q
lactating adenoma
A
- look like FA
- estrogen dependent
- FU 4-6 mo postpartum, post delivery
- regress rapidly after you stop lactation
7
Q
LMO done in ?
A
kyphosis/pectus exca
central line, pacemaker
8
Q
NO BR-3 if ?
A
palablae
new/growing
on SG MG
9
Q
shape on US, MG, MR?
A
Round
oval
irregular
10
Q
MR margin
A
IRREGULAR
spiculated
circusm
11
Q
enlarging Lipoma Mx?
A
Bx
12
Q
PASH MX
A
FU annually
13
Q
phylliod tum ca risk
A
10% >> degenration large > 3 cm might harbour IDC, DCIS, ILC or sarcoma. mets > lung hematogenous Rx: Sx with wide margin > 2 cm. high rate of recurrance if < 2 cm. no CTx ot RTx FU every 6 month?3yr
14
Q
Round IDC DDx
A
mucinous
medullary ( +calc, might have + Ax LAD, lymphiod infiltration on path, BRCA1)
15
Q
ILC
A
dark starolder pt > IDC US: shadowing w/o a mass washout is less common than IDC Ax mets less common 1/5 missed on MG 1/3 b/l
16
Q
MQSA physician req
A
240/6 mo/ last 2yr
960/24 mo
8 CME new
15 CME/36 mo
17
Q
MG facility inspected by FDA each.
eval their physicians compliance
A
year
18
Q
BRCA1
A
ADD
CH. 17 tumor supressor gene
life time risk of BCA: 50-85%
19
Q
MG paddle
A
- 18X24, 24X30 cm.
- 25-45 Ib.
- collimate to detector not br contour.
20
Q
ab interpretation rate = recall rate
A
no. of BR 0, 4,5/ total SG MG
only count SG
21
Q
DG interpretation rate
A
BR 4,5 on DG/ total DG
22
Q
cancer detection rate?
A
+ve Bx/ total SG
23
Q
PEG direction on MRI
A
Ax: LT > RT
Sag: Sup > inf
24
Q
DAILY QC for screen film
A
darkroom cleaniness
processor QC
25
Weekly QC?
screen cleanliness
phantom
viewbox cleanliness
26
Montly?
Visual checklist
27
Quarterly
repeat analysis
| analysis of fixer retention
28
Semi-annually
darkroom fog
screen-film contact
compression
29
ghost artifact on MG 2/2
low temp dtector >> warm it up
30
readout failure artifact 2/2
software failure.
31
GAD Dose use in MRI Br
0.1 mmol/kg
32
detector interface line on MG
2/2 Se based detector. slight differ in caliber of two halves of the detector
33
SG MG
```
cancer detection ra te > 2.5
recall rate: 5-12%
PPV1: 3-8%
PPV: 20-40%
Sn > 75%
Sp 88-95%
```
34
malg risk in calc
coarse hetro: 13%
amorph: 21%
fine pleo 29%
fine branching > 80%
35
HER2 +ve Px
more aggressive vs HER2 negative >> rapid growth and spread
20% of BCA
less responsive to hormonal Rx.
36
MCL of BCA in male
subarloar ( only 1% in F)
37
Interval ca?
cancer detected between SG MG.
| lobular or mucinous
38
male w/ palable mass < 30 ?
US
39
MBI
whole body radiation
Br density does not matter Sn for all
During active phase: b/l patchy GH tX uptake is expected
40
B/l Br edema
```
LAD
SVC obstruction
Psoriasis
Scleroderma
Dermatocytitis
```
41
Poland synd ass cn?
Lung
bCA
Lymphoma leukemia
ARD
42
CI to B RTx
Preg
Hx of Rad
Multi centric or diffuse disease
CVD
43
Focal fibrosis in Post-M
HRT
Usually seen in pre-M
44
When post Sx or RTx C+ subsides ?
String until 9 No
Starts to subside 10-18 months
Very low more than 24 mo
45
Milk fistula risk w/ percut Bx?
Low
Higher with Sx Bx
Start w/ percut one. Should not preclude you from Bx high risk lesion
46
Percentage of Contralateral detected BR cancer ?in MR
3-5%
47
MBI
Small FOV
Rad dose higher than MG
Not affected by density
48
Cysts in men
Men don’t undergo lobular development so no B9 FCC
Concerning finding
49
Round lesion in US BIRAD?
4
3>> oval
50
Fetal dose from SG MG is
<50 mGy
Risk of organ mal and mental retardation > 100mGy if done 3-8 wk
51
MC mets to BR
1st: BCA
2nd: Melanoma
52
RF of gynecomastia
```
Liver failure
thyriod dis ( high and low)
meds: TCA, pred
hypogonadism
testicular failure
mump
KF
COPD
DM
```
Uni: 45%
53
PASH growing next?
excitional Bx because risk of low grade angiosarcoma. they look alike
54
ADH upgrade rate?
1 in5
| 11-50%
55
Inflam BCA
!% only
skin thickening
T4
56
Intraductal pap MX
Consevative
| if atypical or atypia detected >> Sx excitional Bx
57
compression?
- decreased dynamic range
- decreased dose
- increased resolution, contrast.
- decreased
58
is ASA or AC safe with breast Bx?
yes
not for colipdegrol
59
MC compl of Br Sx
seroma
60
absolute CI of breast conservative Rx ( lump + RTx)
1st, 2nd tri preg
Hx of RTx
multicentric diz or diffuse malg calc
positive margin despite wide resection
61
relative CI of breast conservative Sx
CVD
| poor cosomtic outcome.
62
next step if there is imaging-histo discordance follwoing stero or MR Bx>
SX
| dont repeat stearo or MR Bx
63
Max lidocaine dose w/ epi?
7mg/kg, not > 500 mg total
| ratio: 1:100,000
64
Max lido w/o epi?
4.5 mg/kg, not > 300 mg total
65
T/F ALH has to get Sx Bx ?
FALSE
66
compl of percutanous US guided Bx includes?
pseudoaneyrsm
67
ghalactography dose ?
0.2-0.3 ml, dont exceed 1.0 ml
30 G needle
if the pore duct is not identified \>> dont do it
only for single, Unilat, spontanous duct.
only bloody, serous, or yellow discharge.
WHITE or GREEN discahrge >>>> B9
if there is ab >> loc w/ Bx marker or wire during ductoram, not straightforward to sX
DOnt Bx based on stero, you cant see the ab
68
superficial tx lido buffered with NaHCO4 w/ ratio of?
1:9
69
flat epitheleal atypia upgrade rate?
1/3 to high risk lesion or DCIS OR IDC
70
ICL FN rate?
21%
71
Electronic mag results in ?
Same dose and SR
But more noise
Vs geometric mag
72
MBI detector
Cadmium zinc tellirude
